Agenda
Bio-IT World's Second Annual
Bio-IT World Venture, Innovation & Partnering IN-PERSON ONLY
Uniting Investors and Leaders: Advancing Innovation
April 3, 2025 ALL TIMES EDT
Thursday, April 3
Registration and Networking Coffee
Organizer's Welcome Remarks
Optimizing Investment Strategies in Biotech
Stephanie Oestreich, Managing Director, Myeloma Investment Fund of the MMRF
Explore the current landscape of biotech investment and partnerships, focusing on timing, pipeline risk, and today's fundraising challenges. The panel will cover strategies for partnership timing, pipeline management, and navigating financial realities to accelerate clinical outcomes.
Address the Disconnect between Tech VCs and Biotech
Luba Greenwood, CEO, Gallop Oncology
Address the disconnect between tech VCs and biotech regarding capital intensity, compensation, and board structures. Include pharma’s perspective to identify collaborative strategies for funding successful biotech ventures.
How Data Centers Enable Your Enterprise AI /IT Strategy
Matt Senderhauf, Vice President of Interconnection, IT, CoreSite
9 in 10 organizations look to AI to help them gain competitive edge.1 But for AI to be valuable, they need an infrastructure capable of high-density power, high-performance compute and low-latency cloud and digital ecosystem interconnection. CoreSite is an AI accelerator. Access to Cloud - We provide a direct onramp and access to AI-compute capabilities in all public clouds. High-Density, High-Performance Environment – Support new AI workloads, like those applications deployed in our data centers today. Customizable Deployments - Capable of hosting multiple “flavors” of AI processes, just as we do with public cloud providers T. Trusted Partner, Proven Track Record - Organizations specialized in AI-scale data transport and AI-specific services can rely on CoreSite.
Biotech Venture Co-Creation with AI-Powered Drug Discovery Platforms
Barry Duplantis, Director of Global Business Development, Ailux Biologics
Translating biology into novel development candidates requires a competent, comprehensive, and trustworthy team for drug discovery. We will introduce our AI-powered platforms and venture co-creation model with life sciences VCs. This collaboration will allow rapid de-risking and generation of innovative best-in-class biologics that fill unmet medical needs.
Networking Coffee Break
The VC & CEO Relationship, Cultivating Enduring Progress
Scott T. Megaffin, CEO, Adiso Therapeutics
Successful biotech companies often rely on strong partnerships between VCs and the CEO. Our highly experienced panelists will delve into the evolution of this critical relationship, sharing their experiences on building trust, navigating challenges, and aligning strategic visions to drive innovation and growth.
Demystifying AI—Real Examples in Drug Development
Bill Fitzgerald, Head, Biotechnology Markets Americas, Google
Explore how AI is transforming drug development with tangible results. This panel will showcase real-world case studies of AI applications that enhance clinical processes, streamline workflows, and deliver measurable value. Gain clarity on the distinction between AI and generative AI and their unique roles in biotech. With practical demonstrations and insights from industry leaders, this session is designed to equip investors and stakeholders with a comprehensive understanding of AI's potential and its proven ROI in supporting drug discovery.
Executive Perspectives: AI and the Future of Biotech: Investment Opportunities and Market Growth
Join Grant Murphy, PRO Chair of Protein Therapeutics, and Stephen Pagliuca, Founder of Arena BioWorks, as they discuss the future of AI investment in biotech. They’ll share their insights on market growth, emerging opportunities, and how AI is shaping the next wave of innovation in protein therapeutics and beyond. Don’t miss this chance to hear from two industry leaders on the cutting edge of biotech’s transformation.
Networking Luncheon
FIRESIDE CHAT: Investing beyond the Molecule: The Future of Drug Discovery
Derek Lowe, PhD, Director, Chemical Biology & Therapeutics, Novartis BioMedical Research
Join Derek Lowe, Director of Chemical Biology Therapeutics at Novartis Institutes for BioMedical Research, and John Keilty, venture capitalist at Third Rock Ventures, for an in-depth conversation on the evolving role of biology in drug discovery. This session will explore cutting-edge developments and their potential to shape future biotech innovations, providing insights essential for investors and industry leaders looking to understand the next wave of transformative therapies.
The Power Trio: How Big Tech, Pharma, and Finance are Shaping the Future of Life Sciences
Jeremy P. Goldberg, Operating Partner, Healthcare, Arsenal Capital Partners
This panel, will dive deep into how technology, pharma, and finance are driving breakthroughs in Bio-IT and life sciences. The conversation will focus on how advanced technologies are transforming drug discovery, optimizing pharma R&D workflows through AI and data analytics, and how investment banking strategies and healthcare investments are fueling these innovations. It’s going to be a powerful discussion on how tech, pharma, and finance are working together to shape the future of life sciences.
Roundtable Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective problem-solving session, and participate in active idea sharing.
Expanding access to Ginkgo's platform: from Solutions to Solutions + Tools
Barry Canton, PhD, Co-Founder & CTO, Ginkgo BioWorks, Inc.
Ginkgo has built a general-purpose biology platform that is adaptable to evolving industry needs. During COVID, we were able to orient toward pandemic preparedness and response. Now, shifting market dynamics in industrial biotech and biopharma drive us to expand from providing end-to-end cell engineering solutions to also offering direct sales of the tools that power our platform—lab automation, AI models, and lab data generation. This talk covers that evolution.
Can We Improve Affinities of In-Clinic Antibody Drugs by a Further 10x+ Using AI Design and SPOC?
Bharath Takulapalli, Founder & CEO, SPOC Proteomics
Approximately 85% of biologics entering clinical trials fail due lack of safety and/or efficacy. And only about 1 in 10 drugs in early discovery ever reach clinical phase. Integrating therapeutic discovery workflows with SPOC platform and AI-driven design has the potential to reduce these staggering failure rates.
Sensor-integrated proteome on chip (SPOC) is a novel approach that enables on-chip synthesis and simultaneous kinetic analysis of thousands of proteins or sc-antibody drug libraries. SPOC supports rapid DBTL (design-build-test-learn) cycles for AI-driven drug design, facilitates affinity ranking, epitope mapping, and affinity maturation.
Investing in the Future of Drug Discovery: Breakthrough Technologies to Watch
Joe Collura, Director, Co-Founder & CEO, Stealth Mode Biotech
Discover where to invest now to capitalize on the future of drug discovery. This panel will spotlight groundbreaking technologies like quantum computing and advanced platforms that are reshaping the industry. Hear from experts on which innovations hold the most promise, and gain insights to guide smart investment decisions for impactful returns.
Best of Show Awards Reception in the Exhibit Hall with Poster Viewing
Unwind with colleagues at our lively reception! Explore posters, vote for the best, network with exhibitors, enjoy a drink, and try to win a raffle prize. Celebrate Best of Show winners!
Close of Summit